A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease

Trial Profile

A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Imiglucerase (Primary)
  • Indications Gaucher's disease type I
  • Focus Registrational; Therapeutic Use
  • Sponsors ISU Abxis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 14 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top